NL-OMON43305尚未招募不适用
Discovery of non-invasive biomarkers for immune-mediated liver diseases; AIH, DILI, NAFL and NASH. - Discovery of biomarkers for immune-mediated liver diseases.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •* Indication for a biopsy for the diagnosis or monitoring of; AIH, DILI, NAFL or NASH
- •* Eligible for liver biopsy
- •* * 18 years old
- •* Provide informed consent
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •* Contraindication for liver biopsy, determined by the clinician.
- •* Current infectious disease.
- •* Clinically relevant cardiovascular, pulmonary, or renal disease.
- •* Medications with possible immune-modulating effects (e.g., steroids).
- •* History of alcohol or drug abuse.
研究者
相似试验
尚未招募
不适用
Discovery of biomarkers for immune-mediated liver disease.autoimmune hepatitis, drug-induced liver injury, non-alcoholic fatty liver disease and non-alcoholic steatohepatitisNL-OMON24228Investigator initiated study, funded by the Vrije Universiteit, University Medical Center
招募中
不适用
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
进行中（未招募）
不适用
Probiotics and its effect on stress and sleepCTRI/2018/03/012276RGUHS bengaluru
已完成
不适用
Immunological monitoring and assessment of biomarkers predictive of clinical response to first-line treatment with bosutinib or imatinib in chronic phase chronic myeloid leukemiaChronic myeloid leukemiaCML10024324NL-OMON42791Vrije Universiteit Medisch Centrum5
尚未招募
不适用
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000047162Kobe University114